Forsinkede kurser. Sist oppdatert: tirsdag 18. juni  

20/02-2019 14:07:37: (NANO) Nordic Nanovector ASA: Prospectus approved and Repair Offering

Not for release, publication or distribution, directly or indirectly, in the
United States of America, Canada, Japan or Australia
Oslo, Norway, 20 February 2019

Reference is made to the stock exchange announcement on 18 February 2019 where
Nordic Nanovector ASA (the "Company") announced that the extraordinary general
meeting of the Company had granted the Board of Directors an authorisation to
increase the share capital of the Company in connection with a repair offering
of up to 777,777 new shares (the "Offer Shares"), each at a par value of NOK
0.20 at a subscription price of NOK 45.00 per Offer Share (the "Repair
Offering").

The Financial Supervisory Authority of Norway has reviewed and approved the
Company's prospectus regarding the offering and listing of the Offer Shares (the
"Prospectus").

In connection with the Repair Offering, non-transferable subscription rights
(the "Subscription Rights") will be granted to shareholders of the Company as of
24 January 2019, as registered in the Norwegian Central Securities Depositary
(the "VPS") on 28 January 2019 (the "Record Date"), who did not participate in
the private placement of 4,943,094 new shares in the company that were issued on
30 January 2019 (the "Private Placement"), and who are not resident in a
jurisdiction where such offering would be unlawful, or would (in jurisdictions
other than Norway) require any prospectus filing, registration or similar action
(the "Eligible Shareholders").

Each Eligible Shareholder will be granted 1 (one) non-transferable Subscription
Right for each 46 existing shares registered as held by such Eligible
Shareholder at the Record Date. The number of Subscription Rights granted to
each Eligible Shareholder will be rounded down to the nearest whole Subscription
Right. Each Subscription Right gives the right to subscribe for, and be
allocated, one Offer Share in the Repair Offering. Over-subscription and
subscription without Subscription Rights will be permitted; however there can be
no assurance that Offer Shares will be allocated for such subscriptions.

The Subscription Period will begin on 21 February 2019 at 09.00 CET and end on
6 March 2019 at 16:30 CET (the "Subscription Period"). Subscription Rights that
are not used to subscribe for Offer Shares before the expiry of the Subscription
Period will have no value and will lapse without compensation to the holder.

Due Date for payment of the Offer Shares is 8 March 2019. Subject to timely
payment of the Offer Shares subscribed for and allocated in the Repair Offering,
the issuance of the Offer Shares pertaining to the Repair Offering is expected
to be completed on or about 12 March 2019. The Offer Shares are expected to be
delivered to the subscribers and commence trading on the Oslo Stock Exchange on
the same day.

DNB Markets, a part of DNB Bank ASA, is acting as manager for the Repair
Offering. Advokatfirmaet Wiersholm is acting as legal advisor to the Company.

The Prospectus, including the subscription form, is attached to this notice and
will also be available today at www.nordicnanovector.com, and on 21 February
2019 at www.dnb.no/emisjoner. The Prospectus, including the subscription form,
will also be available at the offices of the Company and DNB Markets from the
same dates.

Subscriptions may be made by duly completing and delivering the subscription
form, in accordance with the terms and conditions set out in the Prospects.

Norwegian investors with a VPS account can in addition subscribe for Offer
Shares online at
www.dnb.no/emisjoner (http://www.dnb.no/emisjoner%20from%20%5b20) from 21
February 2019.

For further information, please contact:

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information can be found at
www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading A

Ekstern link: https://newsweb.oslobors.no/message/470138

Nyheten er levert av OBI.